

A Phase 1/2, Open-label, Safety and Dosing Study of Autologous CART Cells (Desmoglein 3 Chimeric Autoantibody Receptor T Cells [DSG3-CAART] or CD19-specific Chimeric Antigen Receptor T Cells [CABA-201]) in Subjects With Active, Pemphigus Vulgaris (RESET-PV)

NCT04422912

Status	RECRUITING
Phase	Phase 1, Phase 2
Sponsor	Cabaletta Bio
Enrollment	40 participants

Key Eligibility Criteria

Inclusion (9)

- Confirmed diagnosis of mPV by prior or screening biopsy and prior positive anti- DSG3 antibody ELISA
- mPV inadequately managed by at least one standard immunosuppressive therapies
- Active mPV at screening
- Anti-DSG3 antibody ELISA positive at screening
- Age e18

... and 4 more (see full listing online)

Exclusion (10)

- Active cutaneous lesions associated with PV that indicates mucocutaneous rather than mucosal-dominant disease
- Rituximab in last 12 months unless PV symptoms have recently worsened or anti-DSG3 antibody titers have recently increased
- Prednisone \gt 0.25mg/kg/day
- Other autoimmune disorder requiring immunosuppressive therapies
- Investigational treatment in last 3 months

... and 5 more (see full listing online)

Locations (13 total)

Stanford University, Dept. of Dermatology, Redwood City, California, United States

UC Davis, Dept. of Dermatology, Sacramento, California, United States

Yale University, New Haven, Connecticut, United States

... and 10 more locations